Literature DB >> 22938479

HER2/neu expression in head and neck squamous cell carcinoma patients is not significantly elevated.

Yasaman Sardari1, Soheil Pardis, Azadeh Andisheh Tadbir, Mohammad Javad Ashraf, Mohammad Javad Fattahi, Hooman Ebrahimi, Sara Purshahidi, Bijan Khademi, Marzieh Hamzavi.   

Abstract

BACKGROUND: HER2/neu, a member of EGFR family, is over expressed in some tumors .The purpose of this study was to determine the salivary level and tissue expression of HER2/neu in patients with head and neck squamous cell carcinoma (HNSCC) and any correlation with clinicopathologic parameters.
METHODS: An enzyme- linked immunosorbent assay (ELISA) was used to evaluate the salivary level and immunohistochemistry (IHC) to assess tissue expression of HER2/neu in 28 patients with HNSCC and 25 healthy controls.
RESULTS: The salivary levels of HER2/neu in HNSCC patients was not significantly higher than in the healthy controls (p>0.005). There was no apparent correlation in salivary HER2/neu level with clinicopathological features such as age, sex, grade, tumor size and nodal status. All HNSCC specimens were positive (membranous or/and cytoplasmic) for HER2/ neu, except one sample. Only one HNSCC specimen was stained in cytoplasm purely. All control specimens were membranous and cytoplasmic positive for HER2/neu. There was a significant difference between cytoplasmic staining in case and control groups (p-value<0.05).
CONCLUSION: In our cases, no overexpression of HER2/neu was observed. Thus, our findings suggested that the use of Her-2 as a salivary marker of HNSCC cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22938479     DOI: 10.7314/apjcp.2012.13.6.2891

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

Review 1.  HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Authors:  Netanya I Pollock; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

Review 2.  Targeting HER (ERBB) signaling in head and neck cancer: An essential update.

Authors:  Jun Zhang; Nabil F Saba; Georgia Zhuo Chen; Dong M Shin
Journal:  Mol Aspects Med       Date:  2015-07-07

3.  Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population.

Authors:  Yumna Adnan; Syed Muhammad Adnan Ali; Muhammad Sohail Awan; Romana Idress; Muhammad Ozair Awan; Hasnain Ahmed Farooqui; Hammad Afzal Kayani
Journal:  PLoS One       Date:  2022-05-11       Impact factor: 3.752

4.  Molecular Targeting of Her-2/neu Protein Is Not Recommended as an Adjuvant Therapy in Oral Squamous Cell Carcinoma and Oral Lichen Planus.

Authors:  Maryam Kouhsoltani; Amirala Aghbali; Behrooz Shokoohi; Ronak Ahmadzadeh
Journal:  Adv Pharm Bull       Date:  2015-12-31

5.  Expression of HER-2/neu in Oral Squamous Cell Carcinoma.

Authors:  Sana Mirza; Naila Hadi; Shahid Pervaiz; Sultan Zeb Khan; Sameer A Mokeem; Tariq Abduljabbar; Nawwaf Al-Hamoudi; Fahim Vohra
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.